694
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction

, , &

References

  • Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, Alexander GC. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–574. doi:10.1146/annurev-publhealth-031914-122957.
  • Breckenridge J, Clark JD. Patient characteristics associated with opioid versus nonsteroidal anti-inflammatory drug management of chronic low back pain. J Pain. 2003;4:344–350. doi:10.1016/s1526-5900(03)00638-2.
  • Garland EL, Froeliger B, Zeidan F, Partin K, Howard MO. The downward spiral of chronic pain, prescription opioid misuse, and addiction: Cognitive, affective, and neuropsychopharmacologic pathways. Neurosci Biobehav Rev. 2013;37:2597–2607. doi:10.1016/j.neubiorev.2013.08.006.
  • Ling W, Mooney L, Hillhouse M. Prescription opioid abuse, pain and addiction: Clinical issues and implications. Drug Alcohol Rev. 2011;30:300–305. doi:10.1111/j.1465-3362.2010.00271.x.
  • Substance Abuse and Mental Health Services Administration. Managing chronic pain in adults with or in recovery from substance use disorders. In Treatment Improvement Protocol(TIP) 54. Rockville (MD): Substance Abuse and Mental Health Administration; 2011.
  • Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and coexistent opioid addiction. J Add Med. 2010;4:140–146. doi:10.1097/ADM.0b013e3181ba895d.
  • Neumann AM, Blondell RD, Jaanimägi U, Giambrone AK, Homish GG, Lozano JR, Kowalik U, Azadfard M. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and co-existent opioid addiction. J Add Dis. 2013;32:68–78. doi:10.1080/10550887.2012.759872.
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR (4th ed.). Washington (DC): American Psychiatric Publishing; 2000.
  • Skinner HA. The drug abuse screening test. Addictive Behav. 1982;7:363–371. doi:10.1016/0306-4603(82)90005-3.
  • Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12:379–384.
  • Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, editors. The pharmachological basis of therapeutics 10th ed. New York (NY): McGraw-Hill; 2001. pp. 251–255.
  • Boonstra AM, Schiphorst Preuper HR, Reneman MF, Posthumus JB, Stewart RE. Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain. Int J Rehabil Res. 2008;31:165–169. doi:10.1097/MRR.0b013e3282fc0f93.
  • Cleeland CS. The brief pain inventory user guide. Houston (TX): The University of Texas; 2009.
  • Roland M, Fairbank J. The Roland-Morris disability questionnaire and the oswestry disability questionnaire. Spine. 2000;25:3115–3124. doi:10.1097/00007632-200012150-00006.
  • Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi:10.1001/archpsyc.1961.01710120031004.
  • Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35:253–259. doi:10.1080/02791072.2003.10400007.
  • Chou R, Cruciani RA, Fiellin DA, Compton P, Farrar JT, Haigney MC, Inturrisi C, Knight JR, Otis-Green S, Marcus SM, et al. Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014;15:321–337. doi:10.1016/j.jpain.2014.01.494.
  • Rosenblum A, Cruciani RA, Strain EC, Cleland CM, Joseph H, Magura S, Marsch LA, McNicholas LF, Savage SR, Sundaram A, et al. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol. J Opioid Manage. 2012;8:369–382. 10.5055/jom.2012.0137
  • Streltzer J, Ziegler P, Johnson B. Cautionary guidelines for the use of opioids in chronic pain. Am J Addict. 2009;18:1–4. doi:10.1080/10550490802544508.
  • Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011;9:CD005031. 10.1002/14651858.CD005031.pub4.
  • Carpenter KJ, Chapman V, Dickenson AH. Neuronal inhibitory effects of mehtadone are predominanlty opioid receptor mediated in the rat spinal cord in vivo. Eur J Pain. 2000;4:19–26. doi:10.1053/eujp.1999.0147.
  • Gordon A, Rashiq S, Moulin DE, Clark AJ, Beaulieu AD, Eisenhoffer J, Piraino PS, Quigley P, Harsanyi Z, Darke AC. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag. 2010;15:169–178. doi:10.1155/2010/216725.
  • Spanagel R, Almeida OFX, Bartl C, Shippenberg TS. Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacol. 1994;115:121–127. doi:10.1007/BF02244761.
  • Knoll A. T, Meloni EG, Thomas JB, Carroll FI, Carlezon W. A. Anxiolytic-like effects of κ-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther. 2007;323:838–845. doi:10.1124/jpet.107.127415.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.